A Phase I Trial of BNC105P and Ibrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia
A Phase I Trial of BNC105P in combination with BTK inhibitor ibrutinib in patients with
relapsed/refractory chronic lymphocytic leukemia(CLL). This study proposes that ibrutinib
will have far greater efficacy when it is combined with drugs that kill the CLL cells in
peripheral circulation, thereby preventing them from returning to the protective lymph node
niche. The study will establish the maximum tolerated dose(MTD) of the combination of BNC105P
with ibrutinib, characterize the pharmacodynamic effects of BNC105P alone and in combination
with ibrutinib in CLL cells, and provide preliminary assessment of the efficacy of the
combination in CLL.
The study consists of a Screening Period with baseline tumor assessment before BNC105P
administration, a Treatment Period with up to six 21-day cycles and Follow-up Period.
Subjects will receive a total of six cycles of therapy unless treatment is discontinued
View more details from ClinicalTrials.gov.
For more information about a clinical trial, clinical trial eligibility, or informed consent, contact our research nurses by phone or email:
Please Note: Any eligibility criteria noted are subject to change. Our research nurses can provide you with the most current eligibility and exclusion criteria. Any study involvement to be undertaken must ultimately be determined on an individual basis.